Spots Global Cancer Trial Database for PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
Official Title: A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)
Study ID: NCT03149549
Interventions
Study Description
Brief Summary: The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001 PROBODY is a trademark of CytomX Therapeutics, Inc
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
Rush University Medical Center, Chicago, Illinois, United States
University of Chicago, Chicago, Illinois, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
New York University (NYU) Clinical Cancer Center, New York, New York, United States
Columbia University College of Physicians & Surgeons, Columbia University, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Providence Portland Medical Center, Portland, Oregon, United States
The Sarah Cannon Research Institute, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Viriginia Cancer Specialists, Fairfax, Virginia, United States
Swedish Cancer Institute (SCI), Seattle, Washington, United States
University of Wisconsin-Carbone Cancer Center, Madison, Wisconsin, United States
Amsterdam UMC - Locatie VUmc, Amsterdam, , Netherlands
Universitair Medisch Centrum Groningen, Groningen, , Netherlands
Clinica Universidad de Navarra, Pamplona, Navarre, Spain
Instituto Catalan de Oncologia - Hospital Duran i Reynals, Barcelona, , Spain
Hospital Clinic Barcelona, Barcelona, , Spain
Centro Integral Oncologico Clara Campal, Madrid, , Spain
Instituto Valenciano de Oncologia, Valencia, , Spain
Beatson, West of Scotland Cancer Centre, Glasgow, , United Kingdom
Sarah Cannon Research Institute UK Limited, London, , United Kingdom
Northern Centre for Cancer Care, Newcastle Upon Tyne, , United Kingdom
Contact Details
Name: Monika Vainorius, MD
Affiliation: CytomX Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
